Crinetics Pharmaceuticals (CRNX) Cash from Investing Activities (2017 - 2026)

Crinetics Pharmaceuticals' Cash from Investing Activities history runs 10 years deep, the most recent figure standing at -$252.4 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 193.57% year-over-year to -$252.4 million; the TTM figure through Mar 2026 stood at $7.5 million (up 101.14% YoY), while the FY2025 annual figure was $173.9 million, up 130.25% from the prior year.
• Cash from Investing Activities was -$252.4 million for Q1 2026 at Crinetics Pharmaceuticals, down from $57.1 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $164.8 million in Q3 2025 to a low of -$542.1 million in Q4 2024.
• Historically, Cash from Investing Activities has averaged -$60.5 million across 5 years, with a median of $309000.0 in 2024.
• Biggest YoY gain for Cash from Investing Activities was 699.93% in 2025; the steepest drop was 27919.09% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at $36.9 million in 2022, then tumbled by 336.91% to -$87.3 million in 2023, then plunged by 520.89% to -$542.1 million in 2024, then surged by 110.53% to $57.1 million in 2025, then tumbled by 541.91% to -$252.4 million in 2026.
• The last three Cash from Investing Activities figures came in at -$252.4 million (Q1 2026), $57.1 million (Q4 2025), and $164.8 million (Q3 2025), per Business Quant data.